Sanara MedTech Inc. reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with total net revenue reaching $103.1 million, a 19% increase from $86.7 million in 2024. This growth was primarily driven by increased sales of its soft tissue repair products, particularly CellerateRX Surgical and BIASURGE, as well as certain bone fusion products. The company achieved a gross profit of $95.6 million, reflecting a gross margin of approximately 93%, up from 91% in the previous year. Despite the revenue growth, Sanara reported a net loss from continuing operations of $393,124, an improvement from a loss of $1.9 million in 2024.
In a strategic shift, Sanara MedTech decided to discontinue its Tissue Health Plus (THP) segment in September 2025 due to persistent losses and a lack of investor interest. This decision resulted in a significant asset impairment charge of $26.5 million related to the THP technology platform, which was classified as discontinued operations. Consequently, the company now operates under a single reportable segment, focusing exclusively on its surgical products. The discontinuation of THP has been reflected in the financial statements, with the operations of this segment excluded from continuing operations.
Operationally, Sanara MedTech has expanded its market presence, securing product contracts with over 4,000 hospitals and engaging surgeons across key specialties in the U.S. The company employed 108 full-time staff as of December 31, 2025, and has been actively working to enhance its distribution network. The company also made strategic investments, including a $9 million investment in Biomimetic Innovations Limited, which is expected to bolster its product offerings in the surgical market. Additionally, Sanara acquired CarePICS, LLC, for $2 million, although the technology from this acquisition was also impaired following the discontinuation of the THP segment.
Looking ahead, Sanara MedTech aims to continue its focus on developing and commercializing transformative surgical technologies. The company has outlined plans to drive additional market penetration and geographic expansion, leveraging its comprehensive product portfolio. Despite the challenges faced in the past year, including the discontinuation of the THP segment, Sanara remains committed to improving clinical outcomes and reducing healthcare costs through its innovative surgical solutions. The company anticipates that its ongoing investments in research and development will support future growth and enhance its competitive position in the surgical market.
About Sanara MedTech Inc.
Sanara MedTech Inc. develops and markets innovative medical technologies for surgical, wound, and skincare applications. Its core segments include Sanara Surgical, offering products like collagen and bone grafts, and Tissue Health Plus, providing value-based wound care services. The company focuses on improving clinical outcomes, reducing healthcare costs, and expanding its product pipeline through partnerships, proprietary innovations, and comprehensive care solutions across the U.S. healthcare continuum.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.